

Sanofi receives marketing approval for diabetes drug Soliqua in India

27 March 2023 | News

Pre-filled	nens containing a	a combination of	f insulin ala	raine 100 U	Inits/ml and	lixisenatide fo	r once-daily dosing
i ic-iiica	Delia collianina i	a combination o	ı iliəulli ala	igilic loo c	riiits/iiil aiid	IINISCHAUGE IV	i Olicc-daliv dosilic

Sanofi (India) has received marketing authorisation for its diabetes drug Soliqua (in pre-filled pen) from the Central Drugs Standard Control Organisation (CDSCO). Soliqua is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies. It comes in once daily dosing of pre-filled pens in fixed-ratio combination (10-40 and 30-60) of insulin glargine and lixisenatide.

Soliqua (10-40 and 30-60 prefilled pens) is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.

According to Dr Shalini Menon, Country Medical Lead, Sanofi (India), "Concerns about hypoglycemia and weight gain are known barriers when advancing diabetes treatments, more so when intensifying to a complex insulin regime. The global Solimix study that included Indian patients, demonstrated that once daily Soliqua provides with weight benefit and less hypoglycaemia when compared with twice daily premixed insulin – thereby becoming a valuable option for endocrinologists."